PCSA
Processa Pharmaceuticals, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.86
−4.12%Nov 4, 2026, 13:00 UTC
Processa Pharmaceuticals announced the appointments of Gregory J. Flesher as chief operating officer and Craig Coburn, Ph.D., to leadership positions.
Source:Oct 29, 2026, 12:00 UTC
Processa Pharmaceuticals appointed Sheila Gujrathi, M.D., as Executive Chair of its board of directors.
Source:Oct 29, 2026, 12:00 UTC
Processa Pharmaceuticals announced a research collaboration with Generian Pharmaceuticals to expand its pipeline.
Source:Oct 29, 2026, 12:00 UTC
The U.S. Food and Drug Administration cleared Processa Pharmaceuticals’ investigational new drug application for a Phase 2 study of VT-7208 in chronic spontaneous urticaria.
Source:Jul 29, 2026, 12:48 UTC
Processa Pharmaceuticals raised $200 million for drug trials.
Source:Jul 29, 2026, 12:48 UTC
Processa Pharmaceuticals acquired Vidya Therapeutics in an all-stock deal on Wednesday, gaining access to its lead candidate targeting immune system diseases.
Source: